FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1456016154> ?p ?o ?g. }

• W1456016154 endingPage "5175" @default.
• W1456016154 startingPage "5175" @default.
• W1456016154 abstract "5175 [Introduction]Her2, a member of ErbB family, plays an important role in the progression of breast cancer (BRCA). Herceptin, which is an anti-cancer agent for Her2, has sufficiently improved clinical outcomes of patients. However, 70 % of patients with BRCA have not displayed the overexpression of Her2. We have demonstrated that HB is a promising target for BRCA therapy in spite of the status of Her2 gene. To provide a promising agent for BRCA patients with or without overexpression of Her2, we examined the suppression of tumorigenicity and alterations in ErbB signals in the use of CRM197, a specific inhibitor for HB.
 [Method]BRCA cell lines, MDA-MB-231, MDA-MB-468, BT549, MCF7, SK-BR-3 and CRL1500 were used in this study. All tissue specimens were obtained from 10 cases with BRCA. Informed consent was already obtained from all patients. We examined mRNA expression index (EI) of EGFR, EGFR ligand and Her2 by real-time PCR and the soluble forms of the EGFR ligands in culture medium by ELISA. We assessed the expression of EGFR, Her2 and tyrosine phosphorylation of EGFR and Her2 by immunoprecipitation and immunoblotting as well as the number of apoptotic cells by flow cytometry after the addition of CRM197, Trastuzumab and Erlotinib into these cell lines. To evaluate the antitumor effects of CRM197, 5x10 6 cells were subcutaneously inoculated on nude mice, and CRM197 (1mg/kg) were injected intraperitoneally each week for four weeks. Each tumor volume was estimated from two dimensional tumor measurements. Data were analyzed using the Mann-Whitney U test. P 3 and 1.56x10 4 , respectively. The addition of CRM197 significantly increased the numbers of apoptotic cells with attenuation of EGFR and/or Her2 activation in all BRCA cell lines. On the other hand, Erlotinib showed in vitro anti-tumor effect with suppression of EGFR signaling in MDA-MB-231 and BT549, while Trastuzumab showed in vitro anti-tumor effect with suppression of Her2 signaling in MCF7 and CRL1500. In the administration of CRM197, the tumor volume on treated mice was significantly reduced, compared to that on untreated mice in all BRCA cell lines. CRM197 induced the attenuation of EGFR signals and the reduction of Her2 expression. These results indicated that CRM197 inhibited the tumor formation through the blockade of EGFR as well as Her2 signals.[Conclusion]HB is a validating target for BRCA with or without overexpression of Her2, and CRM 197 is a broad applicable anti-cancer agent for BRCA therapy." @default.
• W1456016154 created "2016-06-24" @default.
• W1456016154 creator A5002582387 @default.
• W1456016154 creator A5018707982 @default.
• W1456016154 creator A5026727407 @default.
• W1456016154 creator A5052663328 @default.
• W1456016154 creator A5059009308 @default.
• W1456016154 creator A5071399199 @default.
• W1456016154 creator A5075066305 @default.
• W1456016154 date "2008-05-01" @default.
• W1456016154 modified "2023-09-23" @default.
• W1456016154 title "Heparin-binding epidermal growth factor-like growth factor (HB) regulates mammary tumorigenesis through EGFR as well as Her2 signal" @default.
• W1456016154 hasPublicationYear "2008" @default.
• W1456016154 type Work @default.
• W1456016154 sameAs 1456016154 @default.
• W1456016154 citedByCount "0" @default.
• W1456016154 crossrefType "journal-article" @default.
• W1456016154 hasAuthorship W1456016154A5002582387 @default.
• W1456016154 hasAuthorship W1456016154A5018707982 @default.
• W1456016154 hasAuthorship W1456016154A5026727407 @default.
• W1456016154 hasAuthorship W1456016154A5052663328 @default.
• W1456016154 hasAuthorship W1456016154A5059009308 @default.
• W1456016154 hasAuthorship W1456016154A5071399199 @default.
• W1456016154 hasAuthorship W1456016154A5075066305 @default.
• W1456016154 hasConcept C121608353 @default.
• W1456016154 hasConcept C126322002 @default.
• W1456016154 hasConcept C170493617 @default.
• W1456016154 hasConcept C203014093 @default.
• W1456016154 hasConcept C2776362946 @default.
• W1456016154 hasConcept C2778087573 @default.
• W1456016154 hasConcept C2779251935 @default.
• W1456016154 hasConcept C2779256057 @default.
• W1456016154 hasConcept C2779438470 @default.
• W1456016154 hasConcept C2779786085 @default.
• W1456016154 hasConcept C502942594 @default.
• W1456016154 hasConcept C530470458 @default.
• W1456016154 hasConcept C553184892 @default.
• W1456016154 hasConcept C555283112 @default.
• W1456016154 hasConcept C71924100 @default.
• W1456016154 hasConceptScore W1456016154C121608353 @default.
• W1456016154 hasConceptScore W1456016154C126322002 @default.
• W1456016154 hasConceptScore W1456016154C170493617 @default.
• W1456016154 hasConceptScore W1456016154C203014093 @default.
• W1456016154 hasConceptScore W1456016154C2776362946 @default.
• W1456016154 hasConceptScore W1456016154C2778087573 @default.
• W1456016154 hasConceptScore W1456016154C2779251935 @default.
• W1456016154 hasConceptScore W1456016154C2779256057 @default.
• W1456016154 hasConceptScore W1456016154C2779438470 @default.
• W1456016154 hasConceptScore W1456016154C2779786085 @default.
• W1456016154 hasConceptScore W1456016154C502942594 @default.
• W1456016154 hasConceptScore W1456016154C530470458 @default.
• W1456016154 hasConceptScore W1456016154C553184892 @default.
• W1456016154 hasConceptScore W1456016154C555283112 @default.
• W1456016154 hasConceptScore W1456016154C71924100 @default.
• W1456016154 hasLocation W14560161541 @default.
• W1456016154 hasOpenAccess W1456016154 @default.
• W1456016154 hasPrimaryLocation W14560161541 @default.
• W1456016154 hasRelatedWork W1617168769 @default.
• W1456016154 hasRelatedWork W1994298503 @default.
• W1456016154 hasRelatedWork W1995302565 @default.
• W1456016154 hasRelatedWork W1997381761 @default.
• W1456016154 hasRelatedWork W2002817170 @default.
• W1456016154 hasRelatedWork W2056008705 @default.
• W1456016154 hasRelatedWork W2060182728 @default.
• W1456016154 hasRelatedWork W2119870604 @default.
• W1456016154 hasRelatedWork W2206889725 @default.
• W1456016154 hasRelatedWork W2259127997 @default.
• W1456016154 hasRelatedWork W2313282063 @default.
• W1456016154 hasRelatedWork W2317147303 @default.
• W1456016154 hasRelatedWork W2810781529 @default.
• W1456016154 hasRelatedWork W2885658945 @default.
• W1456016154 hasRelatedWork W2900933517 @default.
• W1456016154 hasRelatedWork W2999385732 @default.
• W1456016154 hasRelatedWork W3082507598 @default.
• W1456016154 hasRelatedWork W3083052803 @default.
• W1456016154 hasRelatedWork W3204488838 @default.
• W1456016154 hasRelatedWork W34677177 @default.
• W1456016154 hasVolume "68" @default.
• W1456016154 isParatext "false" @default.
• W1456016154 isRetracted "false" @default.
• W1456016154 magId "1456016154" @default.
• W1456016154 workType "article" @default.